公开(公告)号：US20150157633A1

公开(公告)日：2015-06-11

申请号：US14400001

申请日：2013-05-06

Applicant: The Board of Regents of the University of Texas System

Inventor： Lawrence Lum ,  Michael Roth ,  Baozhi Chen ,  Michael Dodge ,  Chuo Chen

IPC: A61K31/519 ,  A61K31/495 ,  A61K31/42 ,  A61K31/4709 ,  A61K45/06 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/453 ,  A61K31/353 ,  A61K31/444 ,  A61K31/517

CPC classification number: A61K31/519 ,  A61K31/353 ,  A61K31/366 ,  A61K31/42 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/453 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/496 ,  A61K31/517 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.

Abstract translation: 本发明一般涉及蛋白信号传导。 特别地，公开了抑制Wnt蛋白信号通路的化合物。 这些化合物可用于治疗Wnt蛋白信号传导相关疾病和病症如癌症，退行性疾病，II型糖尿病和骨细胞减少症。